公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2021 | Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients | Cheng, Huei-Ru; HUNG-CHIH YANG ; Lin, Su-Ru; Yang, Ta-Yu; Lin, You-Yu; TUNG-HUNG SU ; TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | Hepatology international | 4 | 4 | |
2014 | Commentary: Treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals | Wong V.W.-S.; CHUN-JEN LIU | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
2011 | Community and personal risk factors for hepatitis C virus infection: A survey of 23 820 residents in Taiwan in 1991-2 | Lee M.-H.; Yang H.-I.; Jen C.-L.; Lu S.-N.; Shiou-Hwei Yeh ; CHUN-JEN LIU ; You S.-L.; Sun C.-A.; Wang L.-Y.; WEI J. CHEN ; Chen C.-J.; R.E.V.E.A.L.-HCV Study Group; (CHYI-FENG JAN) | Gut | 49 | 50 | |
2005 | Comparison of a 6-month course peginterferon α-2b plus ribavirin and interferon α-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan | Lee S.-D.; Yu M.-L.; Cheng P.-N.; Lai M.-Y.; Chao Y.-C.; Hwang S.-J.; Chang W.-Y.; Chang T.-T.; Hsieh T.-Y.; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Viral Hepatitis | 78 | 70 | |
2015 | Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping | CHEN-HUA LIU ; Liang C.-C; CHUN-JEN LIU ; Lin C.-L; TUNG-HUNG SU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Clinical Microbiology | 58 | 55 | |
1990 | Complications of bone marrow transplantation in Chinese. | Chen P.M.; Fan S.; CHUN-JEN LIU ; Hsieh R.K.; Liu J.H.; Chuang M.W.; Liu R.S.; Tzeng C.H. | Haematology and blood transfusion | 3 | 0 | |
2023 | Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection | Shih, Yi Fen; Liu, Chieh; CHUN-JEN LIU | Comprehensive Guide to Hepatitis Advances | | | |
2014 | Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries | Dan Y.Y.; Wong J.B.; Hamid S.S.; Han K.-H.; Jia J.D.; CHUN-JEN LIU ; Piratvisuth T.; Lok A.S.F.; Lim S.G. | Hepatology International | 10 | 8 | |
2013 | Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: A multicentre study | Dai C.-Y.; TAI-CHUNG TSENG ; Wong G.L.H.; Huang J-F.; Wong V.W.S.; CHUN-JEN LIU ; Yu M.-L.; Chuang W.-L.; JIA-HORNG KAO ; Yuen Chan H.L.; DING-SHINN CHEN | Journal of Antimicrobial Chemotherapy | 20 | 19 | |
2008 | Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: Story beyond A1762T/G1764A mutations | CHUN-JEN LIU ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 5 | 5 | |
2021 | Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients | Cheng, Huei-Ru; HUNG-CHIH YANG ; Lin, Su-Ru; Yang, Ta-Yu; Lin, You-Yu; TUNG-HUNG SU ; TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | Hepatology international | 0 | 0 | |
2023 | Correction: Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease | Lin, Meng-Ju; TUNG-HUNG SU ; CHIEH-CHANG CHEN ; WEI-KAI WU ; SHIH-JER HSU ; TAI-CHUNG TSENG ; SIH-HAN LIAO ; CHUN-MING HONG ; HUNG-CHIH YANG ; CHUN-JEN LIU ; MING-SHIANG WU ; JIA-HORNG KAO | Gut pathogens | 0 | 0 | |
2014 | The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo | Lin S.-R.; HUNG-CHIH YANG ; Kuo Y.-T; CHUN-JEN LIU ; Yang T.-Y; Sung K.-C; Lin Y.-Y; HURNG-YI WANG ; Wang C.-C; Shen Y.-C; Wu F.-Y; JIA-HORNG KAO ; DING-SHINN CHEN ; PEI-JER CHEN | Molecular Therapy - Nucleic Acids | 325 | 301 | |
2019 | Decreased Colorectal Adenoma Risk after Helicobacter pylori Eradication: A Retrospective Cohort Study | Hu K.-C.; MING-SHIANG WU ; Chu C.-H.; Wang H.-Y.; Lin S.-C.; Liu C.-C.; TUNG-HUNG SU ; WEI-CHIH LIAO ; CHI-LING CHEN ; CHUN-JEN LIU ; Shih S.-C. | Clinical Infectious Diseases | 15 | 14 | |
2009 | Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year follow-up study | MEI-HWEI CHANG ; You S.-L.; Chen C.-J.; CHUN-JEN LIU ; Lee C.-M.; Lin S.-M.; Chu H.-C.; Wu T.-C.; Yang S.-S.; Kuo H.-S.; DING-SHINN CHEN | Journal of the National Cancer Institute | 494 | 408 | |
2019 | Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers | KAI-CHI CHANG ; MEI-HWEI CHANG ; CHIEN-NAN LEE ; Chang C.-H.; JIA-FENG WU ; YEN-HSUAN NI ; Wen W.-H.; MING-KWANG SHYU ; Lai M.-W.; Chen S.-M.; Hu J.-J.; Lin H.H.; Hsu J.-J.; Mu S.-C.; Lin Y.-C.; CHUN-JEN LIU ; DING-SHINN CHEN ; Lin L.-H.; HUEY-LING CHEN ; HSIAO-LIN HWA ; Su Y.-N.; JIN-CHUNG SHIH ; KUANG-HAN CHAO ; HONG-YUAN HSU ; YU-CHUN CHIU ; TUNG-HUNG SU ; Lin C.-C.; Lin P.-Y.; Yang W.-R.; Zhao L.-L.; Yang C.-K.; Chang Y.-K.; Chen K.-H.; Lin Y.-H.; Chen H.-J.; Pan H.-S.; Lau B.-H.; Lee C.-L.; Cheng P.-J.; Chang Y.-L.; Chiueh H.-Y.; Wang T.-H.; Lo L.-M.; Hsieh C.-L.; Cheng S.-W.; Tsai M.-S.; She B.-Q.; Koh K.-J.; Hung Y.-L.; Lin H.-M.; Peng F.-S.; Wu T.-C.; Chen C.-Y.; Chen C.-P.; Huang J.-P.; Yeung C.-Y.; Lin C.-J.; Chiu W.-T.; Wang D.-S.; Lin W.-T.; Hwang K.-S.; Huang C.-F.; The Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study) | Alimentary Pharmacology and Therapeutics | 19 | 18 | |
2012 | Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load | TAI-CHUNG TSENG ; CHUN-JEN LIU ; HUNG-CHIH YANG ; TUNG-HUNG SU ; Wang C.-C; CHI-LING CHEN ; Fang-Tzu Kuo S; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology | 129 | 115 | |
2015 | Development of risk scoring system for stratifying population for hepatocellular carcinoma screening | Hung Y.-C.; Lin C.-L.; CHUN-JEN LIU ; Hung Hung ; Lin S.-M.; Lee S.-D.; PEI-JER CHEN ; Chuang S.-C.; MING-WHEI YU | Hepatology | 38 | 39 | |
2012 | Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy | WANG-HUEI SHENG ; CHIEN-CHING HUNG ; SUI-YUAN CHANG ; CHUN-JEN LIU ; Chen M.-Y.; SZU-MIN HSIEH ; JIA-HORNG KAO ; PEI-JER CHEN ; SHAN-CHWEN CHANG | Clinical Infectious Diseases | 13 | 12 | |
2010 | Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B | Huang Y.-W.; Chayama K.; Tsuge M.; Takahashi S.; Hatakeyama T.; Abe H.; Hu J.-T.; CHUN-JEN LIU ; Lai M.-Y.; DING-SHINN CHEN ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 39 | 38 | |